HER2-neg and CLDN 18.2 pos gastric or gastroesophageal junction adenocarcinoma

HER2-negative and CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma refers to a biologically defined subset of epithelial malignancies originating in the stomach or the gastroesophageal junction This clinical state affects adult gastrointestinal oncology patients whose tumor cells lack human epidermal growth factor receptor 2 overexpression or gene amplification, excluding them from HER2-targeted regimens This biomarker profile delineates an aggressive upper gastrointestinal ...

HER2-negative and CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma refers to a biologically defined subset of epithelial malignancies originating in the stomach or the gastroesophageal junction

This clinical state affects adult gastrointestinal oncology patients whose tumor cells lack human epidermal growth factor receptor 2 overexpression or gene amplification, excluding them from HER2-targeted regimens Pathophysiologically, the tumor demonstrates preserved and exposed surface expression of claudin 18.2—a tight junction protein typically restricted to differentiated gastric mucosal cells—commonly defined by immunohistochemistry showing moderate-to-strong membranous staining in at leas...

Pathophysiologically, the tumor demonstrates preserved and exposed surface expression of claudin 18.2—a tight junction protein typically restricted to differentiated gastric mucosal cells—commonly defined by immunohistochemistry showing moderate-to-strong membranous staining in at least 75% of tumor cells

Pathophysiologically, the tumor demonstrates preserved and exposed surface expression of claudin 18.2—a tight junction protein typically restricted to differentiated gastric mucosal cells—commonly defined by immunohistochemistry showing moderate-to-strong membranous staining in at least 75% of tumor cells